TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06261060: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$2,988,000

Rescue Site Savings

+$1,958,800

Unlock Full NCT06261060 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06261060 Rescue Dossier →